Published online Nov 16, 2021. doi: 10.12998/wjcc.v9.i32.10013
Peer-review started: July 2, 2021
First decision: July 15, 2021
Revised: July 29, 2021
Accepted: September 10, 2021
Article in press: September 10, 2021
Published online: November 16, 2021
Processing time: 130 Days and 8.4 Hours
Uretero-arterial fistula (UAF) is a disease that usually involves the aorta, common iliac artery, external iliac artery, hypogastric artery, and lumbar artery. Among them, uretero-lumbar artery fistula (ULAF) is the most unusual type. So, both in China and around the world, the diagnosis and treatment of ULAF is a big challenge.
A 55-year-old female patient with a history of pelvic radiotherapy developed unexplained massive hemorrhage during replacement of the right Resonance metallic ureteral double-J tubes due to a long-standing indwelling ureteral stent for ureteral stricture. Later, we found contrast extravasation from the patient's right L4 artery into the ureter under digital subtraction angiography (DSA) and administered polyvinyl alcohol particle embolic agent and coil embolization; hematuria was controlled. Follow-up investigations at 18 mo showed no sign of recurrence.
DSA is very important in the diagnosis and treatment of UAF, and DSA should be preferred when UAF is suspected. In addition, the use of softer ureteral stents in patients with primary disease and risk factors for UAF should be considered to avoid increasing the risk of the development of the disease; endovascular treatment should be preferred in patients who have developed UAF.
Core Tip: Uretero-arterial fistula (UAF) has an unclear etiology due to the small number of cases. Uretero-lumbar artery fistula is the least common type of UAF. We report the case of a patient with uretero-lumbar artery fistula in whom we embolized the patient's right L4 artery under digital subtraction angiography, and hematuria was controlled. This case highlights the importance of digital subtraction angiography in the diagnosis and treatment of UAF. We recommend the use of softer ureteral stents in patients with primary disease and risk factors for UAF to avoid increasing the risk of the development of the disease; endovascular treatment should be preferred in patients who have developed UAF.